Antibe Therapeutics, Inc. (Otc) (TSE:ATE) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Antibe Therapeutics Inc. has secured temporary protection from its creditors through the Companies’ Creditors Arrangement Act, with Deloitte Restructuring Inc. overseeing the process as the court-appointed Monitor. The protection, which halts enforcement actions such as the US$24 million payment to Nuance Pharma, will last until April 18, 2024, when Antibe will seek an extension to resolve issues with a U.S. FDA hold on a planned trial. Following these events, trading of Antibe’s common shares was suspended on the Toronto Stock Exchange.
For further insights into TSE:ATE stock, check out TipRanks’ Stock Analysis page.